NCT06180993View on ClinicalTrials.gov

Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization

RecruitingOBSERVATIONAL
Enrollment

42,000

Participants

Timeline

Start Date

September 25, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

October 31, 2026

Conditions
RSV Infection
Interventions
BIOLOGICAL

Nirsevimab

Nirsevimab will be administered administered in a single dose at birth for birth cohort and at the beginning of the campaign for the other cohorts under study

Trial Locations (1)

15707

RECRUITING

Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela

All Listed Sponsors
lead

Federico Martinón Torres

OTHER